CL2013001731A1 - Una combinacion farmaceutica sinergica que comprende orlistat o sus sales y resveratrol o sus sales; composicion farmaceutica que comprende a dicha combinacion sinergica; su proceso de preparacion; y su uso para el tratamiento de padecimientos de sobrepeso, obesidad y problemas de salud relacionados. - Google Patents
Una combinacion farmaceutica sinergica que comprende orlistat o sus sales y resveratrol o sus sales; composicion farmaceutica que comprende a dicha combinacion sinergica; su proceso de preparacion; y su uso para el tratamiento de padecimientos de sobrepeso, obesidad y problemas de salud relacionados.Info
- Publication number
- CL2013001731A1 CL2013001731A1 CL2013001731A CL2013001731A CL2013001731A1 CL 2013001731 A1 CL2013001731 A1 CL 2013001731A1 CL 2013001731 A CL2013001731 A CL 2013001731A CL 2013001731 A CL2013001731 A CL 2013001731A CL 2013001731 A1 CL2013001731 A1 CL 2013001731A1
- Authority
- CL
- Chile
- Prior art keywords
- salts
- synergistic
- combination
- orlistat
- resveratrol
- Prior art date
Links
- 150000003839 salts Chemical class 0.000 title 2
- 208000008589 Obesity Diseases 0.000 title 1
- 206010033307 Overweight Diseases 0.000 title 1
- QNVSXXGDAPORNA-UHFFFAOYSA-N Resveratrol Natural products OC1=CC=CC(C=CC=2C=C(O)C(O)=CC=2)=C1 QNVSXXGDAPORNA-UHFFFAOYSA-N 0.000 title 1
- LUKBXSAWLPMMSZ-OWOJBTEDSA-N Trans-resveratrol Chemical compound C1=CC(O)=CC=C1\C=C\C1=CC(O)=CC(O)=C1 LUKBXSAWLPMMSZ-OWOJBTEDSA-N 0.000 title 1
- 230000005802 health problem Effects 0.000 title 1
- 235000020824 obesity Nutrition 0.000 title 1
- AHLBNYSZXLDEJQ-FWEHEUNISA-N orlistat Chemical compound CCCCCCCCCCC[C@H](OC(=O)[C@H](CC(C)C)NC=O)C[C@@H]1OC(=O)[C@H]1CCCCCC AHLBNYSZXLDEJQ-FWEHEUNISA-N 0.000 title 1
- 229960001243 orlistat Drugs 0.000 title 1
- 239000008194 pharmaceutical composition Substances 0.000 title 1
- 238000002360 preparation method Methods 0.000 title 1
- 229940016667 resveratrol Drugs 0.000 title 1
- 235000021283 resveratrol Nutrition 0.000 title 1
- 230000002195 synergetic effect Effects 0.000 title 1
- 239000011885 synergistic combination Substances 0.000 title 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
- A61K31/05—Phenols
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/365—Lactones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1629—Organic macromolecular compounds
- A61K9/1652—Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/167—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction with an outer layer or coating comprising drug; with chemically bound drugs or non-active substances on their surface
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/5005—Wall or coating material
- A61K9/5021—Organic macromolecular compounds
- A61K9/5036—Polysaccharides, e.g. gums, alginate; Cyclodextrin
- A61K9/5042—Cellulose; Cellulose derivatives, e.g. phthalate or acetate succinate esters of hydroxypropyl methylcellulose
- A61K9/5047—Cellulose ethers containing no ester groups, e.g. hydroxypropyl methylcellulose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C39/00—Compounds having at least one hydroxy or O-metal group bound to a carbon atom of a six-membered aromatic ring
- C07C39/205—Compounds having at least one hydroxy or O-metal group bound to a carbon atom of a six-membered aromatic ring polycyclic, containing only six-membered aromatic rings as cyclic parts with unsaturation outside the rings
- C07C39/21—Compounds having at least one hydroxy or O-metal group bound to a carbon atom of a six-membered aromatic ring polycyclic, containing only six-membered aromatic rings as cyclic parts with unsaturation outside the rings with at least one hydroxy group on a non-condensed ring
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D305/00—Heterocyclic compounds containing four-membered rings having one oxygen atom as the only ring hetero atoms
- C07D305/02—Heterocyclic compounds containing four-membered rings having one oxygen atom as the only ring hetero atoms not condensed with other rings
- C07D305/04—Heterocyclic compounds containing four-membered rings having one oxygen atom as the only ring hetero atoms not condensed with other rings having no double bonds between ring members or between ring members and non-ring members
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D305/00—Heterocyclic compounds containing four-membered rings having one oxygen atom as the only ring hetero atoms
- C07D305/02—Heterocyclic compounds containing four-membered rings having one oxygen atom as the only ring hetero atoms not condensed with other rings
- C07D305/10—Heterocyclic compounds containing four-membered rings having one oxygen atom as the only ring hetero atoms not condensed with other rings having one or more double bonds between ring members or between ring members and non-ring members
- C07D305/12—Beta-lactones
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2200/00—Function of food ingredients
- A23V2200/30—Foods, ingredients or supplements having a functional effect on health
- A23V2200/332—Promoters of weight control and weight loss
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2121/00—Preparations for use in therapy
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Molecular Biology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Diabetes (AREA)
- Obesity (AREA)
- Hematology (AREA)
- Child & Adolescent Psychology (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
MX2010014484A MX336980B (es) | 2010-12-21 | 2010-12-21 | Combinacion y composicion para el tratamiento de obesidad. |
Publications (1)
Publication Number | Publication Date |
---|---|
CL2013001731A1 true CL2013001731A1 (es) | 2014-01-10 |
Family
ID=46313244
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CL2013001731A CL2013001731A1 (es) | 2010-12-21 | 2013-06-14 | Una combinacion farmaceutica sinergica que comprende orlistat o sus sales y resveratrol o sus sales; composicion farmaceutica que comprende a dicha combinacion sinergica; su proceso de preparacion; y su uso para el tratamiento de padecimientos de sobrepeso, obesidad y problemas de salud relacionados. |
Country Status (15)
Country | Link |
---|---|
US (1) | US9433602B2 (es) |
AR (1) | AR084435A1 (es) |
BR (1) | BR112013015489A2 (es) |
CA (1) | CA2822213C (es) |
CL (1) | CL2013001731A1 (es) |
CO (1) | CO6751242A2 (es) |
CR (1) | CR20130298A (es) |
DO (1) | DOP2013000144A (es) |
ES (1) | ES2422877B1 (es) |
GB (1) | GB2500357B (es) |
GT (1) | GT201300169A (es) |
MX (1) | MX336980B (es) |
PE (1) | PE20140697A1 (es) |
RU (1) | RU2608928C2 (es) |
WO (1) | WO2012085785A1 (es) |
Families Citing this family (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US10743813B2 (en) | 2014-09-11 | 2020-08-18 | Rattan Nath | Diabetes control using postprandial feedback |
WO2016168388A2 (en) | 2015-04-14 | 2016-10-20 | Palatin Technologies, Inc. | Therapies for obesity, diabetes and related indications |
Family Cites Families (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE19539361A1 (de) * | 1995-10-23 | 1997-04-24 | Basf Ag | Verfahren zur Herstellung von mehrschichtigen, festen Arzneiformen zur oralen oder rektalen Verabreichung |
GB9914744D0 (en) * | 1999-06-24 | 1999-08-25 | Knoll Ag | Therapeutic agents |
EP1457206A1 (en) * | 2003-03-13 | 2004-09-15 | Fournier Laboratories Ireland Limited | Combined use of a fibrate and orlistat for the treatment of obesity |
US8017634B2 (en) * | 2003-12-29 | 2011-09-13 | President And Fellows Of Harvard College | Compositions for treating obesity and insulin resistance disorders |
EP1838273A4 (en) * | 2005-01-10 | 2013-02-20 | Elc Man Llc | DISCONTINUOUS SURFACE COATING FOR PARTICLES |
AU2006269459B2 (en) * | 2005-07-07 | 2013-02-07 | Sirtris Pharmaceuticals, Inc. | Methods and related compositions for treating or preventing obesity, insulin resistance disorders, and mitochondrial-associated disorders |
US7771632B2 (en) * | 2006-05-15 | 2010-08-10 | American Leistritz Extruder Corp. | Continuous melt spheronization apparatus and process for the production of pharmaceutical pellets |
WO2009039157A2 (en) * | 2007-09-17 | 2009-03-26 | Dr. Reddy's Laboratories Ltd. | Orlistat pharmaceutical formulations |
US20100113580A1 (en) * | 2008-10-16 | 2010-05-06 | Aronne Louis J | Combination therapies for the treatment of obesity |
-
2010
- 2010-12-21 MX MX2010014484A patent/MX336980B/es active IP Right Grant
-
2011
- 2011-12-16 PE PE2013001445A patent/PE20140697A1/es active IP Right Grant
- 2011-12-16 US US13/996,410 patent/US9433602B2/en active Active
- 2011-12-16 ES ES201390069A patent/ES2422877B1/es active Active
- 2011-12-16 BR BR112013015489-6A patent/BR112013015489A2/pt not_active Application Discontinuation
- 2011-12-16 GB GB1312583.6A patent/GB2500357B/en not_active Expired - Fee Related
- 2011-12-16 WO PCT/IB2011/055723 patent/WO2012085785A1/es active Application Filing
- 2011-12-16 RU RU2013127794A patent/RU2608928C2/ru not_active IP Right Cessation
- 2011-12-16 CA CA2822213A patent/CA2822213C/en active Active
- 2011-12-20 AR ARP110104818A patent/AR084435A1/es unknown
-
2013
- 2013-06-14 CL CL2013001731A patent/CL2013001731A1/es unknown
- 2013-06-19 CR CR20130298A patent/CR20130298A/es unknown
- 2013-06-20 DO DO2013000144A patent/DOP2013000144A/es unknown
- 2013-06-21 GT GT201300169A patent/GT201300169A/es unknown
- 2013-06-28 CO CO13153451A patent/CO6751242A2/es unknown
Also Published As
Publication number | Publication date |
---|---|
CA2822213C (en) | 2018-06-19 |
GB2500357B (en) | 2017-09-06 |
AR084435A1 (es) | 2013-05-15 |
ES2422877R1 (es) | 2013-09-26 |
CA2822213A1 (en) | 2012-06-28 |
US9433602B2 (en) | 2016-09-06 |
BR112013015489A2 (pt) | 2018-05-15 |
RU2013127794A (ru) | 2015-01-27 |
GB201312583D0 (en) | 2013-08-28 |
ES2422877B1 (es) | 2014-07-17 |
GT201300169A (es) | 2014-04-04 |
CR20130298A (es) | 2013-07-09 |
DOP2013000144A (es) | 2013-10-15 |
WO2012085785A1 (es) | 2012-06-28 |
US20130316005A1 (en) | 2013-11-28 |
RU2608928C2 (ru) | 2017-01-26 |
PE20140697A1 (es) | 2014-06-25 |
CO6751242A2 (es) | 2013-09-16 |
GB2500357A (en) | 2013-09-18 |
MX336980B (es) | 2016-02-09 |
MX2010014484A (es) | 2012-06-21 |
ES2422877A2 (es) | 2013-09-16 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CL2014000732A1 (es) | Compuestos derivados heterociclicos para su uso en la prevencion o tratamiento de una infeccion por flavivirus; metodo para su preparacion; y composicion farmaceutica que los comprende. | |
CL2014002873A1 (es) | Compuestos derivados de pirimidin-amina o triazin-amina, inhibidores de adn-pk; composicion farmaceutica; y su uso para el tratamiento del cancer. | |
BR112015003332A2 (pt) | composto, composição farmacêutica, uso do composto e método para tratar uma doença ou condição mediada por rorgammat em um paciente | |
BR112015003398A2 (pt) | composto, composição farmacêutica, uso do composto e método para tratar uma doença ou condição mediada por rorgammat em um paciente | |
CL2014000801A1 (es) | Variante de factor 21 de crecimiento de fibroblasto humano (fgf21); composicion farmaceutica que lo comprende; y su uso para tratar diabetes tipo 2, obesidad, dislipidemia, sindrome metabolico o cualquier combinacion de los mismos. | |
CL2013001338A1 (es) | Compuestos derivados de benzotieno-piridinas sustituidas, inhibidores de la replicacion del vih; composicion farmaceutica que los comprende; combinacion farmaceutica; kit farmaceutico; y su uso para el tratamiento del vih. | |
CL2008001002A1 (es) | Compuestos derivados de oxazolidinona; composicion farmaceutica que comprende a dichos compuestos; y su uso para preparar un medicamento para tratar una infeccion bacteriana. | |
BR112014010177A2 (pt) | composto, composição farmacêutica, uso do composto, e, método para a profilaxia ou tratamento de um estado ou uma condição de doença | |
AR079160A1 (es) | Composicion farmaceutica que comprende una sal de estroncio, vitamina d y una ciclodextrina | |
BR112013031794A2 (pt) | novos derivados de oxintomodulina e composição farmacêutica para o tratamento da obesidade compreendendo os mesmos | |
BR112015001596A2 (pt) | composição para o tratamento de hiperlipidemia que compreende oxintomodulina. | |
CL2008001003A1 (es) | Compuestos derivados de oxazolidinona; composicion farmaceutica que comprende a dichos compuestos; y su uso para preparar un medicamento para tratar una infeccion bacteriana. | |
CL2011003350A1 (es) | Compuestos derivados de heterociclo nitrogenados, moduladores pkm2; composicion farmaceutica que los comprende; y su uso en el tratamiento del cancer. | |
HN2012000023A (es) | Compuestos y composiciones para el tratamiento de enfermedades parasitarias | |
BR112014010179A2 (pt) | composto, composição farmacêutica, uso de um composto, e, método para a profilaxia ou tratamento de um estado ou condição | |
BR112012020719A2 (pt) | formulação herbicida método de tratamento de plantas com herbicida método de aumento da eficácia de uma formulação herbicida, e, uso de uma composição | |
BR112012015327A2 (pt) | aparelho para esterilização por vapor | |
BRPI1009781A2 (pt) | compostos para o tratamento de distúrbios metabólicos, composição farmacêutica que os compreende e uso dos mesmos | |
BRPI1010617A2 (pt) | uso de uma composição, composição, uso não médico da composição, e, método para preprar uma composição. | |
BRPI0914410A2 (pt) | composição de polidesoxirribonucleotídeo injetável para o tratamento de doenças osteoarticulares. | |
BRPI0917661A2 (pt) | produto que contém macitentan, composição farmacêutica que o contém e uso de macitentan | |
BRPI1010300A2 (pt) | processos para a preparação de um composto, para perparar dronedarone, ou um sal do mesmo, e para preparar uma formulação farmacêutica. | |
BRPI0912687A2 (pt) | uso de bactéria probiótica para o tratamento de hiperhomocisteinaemia | |
BR112014020008A8 (pt) | composição farmacêutica, uso da mesma, e, processo para a fabricação de uma formulação. | |
BRPI0806944A2 (pt) | Medicamento para o tratamento de endometriose |